Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
| ▸ | GPR55 | Q9Y2T6 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 11/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 10/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 9/20 | 0.43 |
| ▸ | USP2 | O75604 | 8/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | OPRD1 | P41143 | 2/20 | 0.39 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.39 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.39 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19341630 | 0.89 | CYP2D6 (0.45) | CYP3A4CYP2D6CYP2C9USP2CYP1A2 | |
| SCHEMBL23856756 | 0.79 | CYP2D6 (0.47) | NPSR1GPR55CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL17611773 | 0.77 | OPRM1 (0.42) | CYP3A4CYP2D6OPRD1OPRM1OPRK1 | |
| SCHEMBL17611693 | 0.77 | OPRM1 (0.43) | CYP3A4CYP2D6CYP2C9USP2OPRD1 | |
| SCHEMBL21739433 | 0.75 | TOP2A (0.33) | ALDH1A1TDP1 | |
| SCHEMBL1121779 | 0.74 | CYP3A4 (0.51) | NPSR1GPR55CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL1244969 | 0.74 | NPSR1 (0.54) | NPSR1GPR55CYP3A4CYP2D6CYP2C9 | |
| Hydrochloric Acid SCHEMBL1246878 | 0.72 | NPSR1 (0.52) | NPSR1GPR55CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL21640238 | 0.68 | CYP2D6 (0.44) | NPSR1GPR55CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL17609035 | 0.68 | SIGMAR1 (0.56) | CYP3A4CYP2D6OPRD1OPRM1OPRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9908897-B2 | Spirocyclic derivatives | CHRONOS THERAPEUTICS LIMITED (GB) | 2018-03-06 | — | — | US | disclosed |
| US-9908897-B2 | Spirocyclic derivatives | CHRONOS THERAPEUTICS LIMITED (GB) | 2018-03-06 | — | — | US | disclosed |
| US-20170253615-A1 | Spirocyclic derivatives | SHIRE INTERNATIONAL GMBH (CH) | 2017-09-07 | — | — | US | disclosed |
| US-20170253615-A1 | Spirocyclic derivatives | SHIRE INTERNATIONAL GMBH (CH) | 2017-09-07 | — | — | US | disclosed |
| US-20170253615-A1 | Spirocyclic derivatives | SHIRE INTERNATIONAL GMBH (CH) | 2017-09-07 | — | — | US | disclosed |
| EP-3201195-A1 | SPIROCYCLIC DERIVATIVES | Chronos Therapeutics Limited (GB) | 2017-08-09 | — | — | EP | disclosed |
| WO-2016042452-A1 | Spirocyclic derivatives | SHIRE INTERNATIONAL GMBH (CH) | 2016-03-24 | — | — | WO | disclosed |
| WO-2016042452-A1 | Spirocyclic derivatives | SHIRE INTERNATIONAL GMBH (CH) | 2016-03-24 | — | — | WO | disclosed |
| US-8629271-B2 | Compounds | ASTRAZENECA AB (GB) | 2014-01-14 | — | — | US | disclosed |
| US-8629271-B2 | Compounds | ASTRAZENECA AB (GB) | 2014-01-14 | — | — | US | disclosed |
| US-8148373-B2 | Compounds | ASTRAZENECA AB (SE) | 2012-04-03 | — | — | US | disclosed |
| US-8148373-B2 | Compounds | ASTRAZENECA AB (SE) | 2012-04-03 | — | — | US | disclosed |
| US-20110053909-A1 | Compounds - 801 | PULMAGEN THERAPEUTICS (SYNERGY) LIMITED (GB) | 2011-03-03 | — | — | US | disclosed |
| WO-2011012896-A2 | COMPOUNDS - 801 | ASTRAZENECA AB (SE) | 2011-02-03 | — | — | WO | disclosed |
| EP-2242759-A1 | COMPOUNDS | AstraZeneca AB (SE) | 2010-10-27 | — | — | EP | disclosed |
| US-20090298807-A1 | Compounds | ASTRAZENECA AB (SE) | 2009-12-03 | — | — | US | disclosed |
| US-20090298807-A1 | Compounds | ASTRAZENECA AB (SE) | 2009-12-03 | — | — | US | disclosed |
| US-20090298807-A1 | Compounds | ASTRAZENECA AB (SE) | 2009-12-03 | — | — | US | disclosed |
| WO-2009098448-A1 | COMPOUNDS | ASTRAZENECA AB (SE) | 2009-08-13 | — | — | WO | disclosed |
| WO-2009098448-A1 | COMPOUNDS | ASTRAZENECA AB (SE) | 2009-08-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170253615-A1 | Spirocyclic derivatives | SLC6A3, SLC10A1, ABCB11 | NPSR1 151/4885GPR55 909/4885CYP3A4 1808/4885 |
| US-20090298807-A1 | Compounds | PKD1, SLC10A1, ABCB11 | NPSR1 499/4885GPR55 1259/4885CYP3A4 60/4885 |
| US-20110053909-A1 | Compounds - 801 | ADRA2C, ADRB2, ADRB1 | NPSR1 140/4885GPR55 254/4885CYP3A4 532/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.